A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.

被引：0
|
作者：
Mackay, HJ
Major, P
Townsley, C
Mackenzie, M
Vincent, M
Boudreau, T
Tsao, M
Hedley, D
Wright, J
Siu, L
Moore, M
Oza, AM
机构：
[1] Princess Margaret Hosp Phase II Consortium, Toronto, ON, Canada
[2] NCI, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6201S / 6201S
页数：1
相关论文
共 50 条
  • [1] A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer
    Mackay, H
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Degendorfer, P
    Tsao, M
    Hedley, D
    Wright, J
    Oza, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 222S - 222S
  • [2] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [3] A phase 8 and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib ,velcade), in patients with advanced cancer
    Dy, GK
    Thomas, JP
    Wilding, G
    Bruzek, L
    Mandrekar, S
    Erlichman, C
    Alberti, D
    Binger, K
    Pitot, HC
    Alberts, SR
    Hanson, LJ
    Marnocha, R
    Tutsch, K
    Kaufmann, SH
    Adjei, AA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3410 - 3416
  • [4] Proteosome inhibitor PS-341 (velcade) causes cell growth arrest and apoptosis in colorectal carcinomas
    Al-Sanea, N.
    Abdul, Jabbar A.
    Ashad, L.
    Alhomoud, S.
    Al-Jomah, N.
    Ahmed, M.
    Hussain, A.
    Uddin, S.
    Al-Kuraya, K.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII32 - VII32
  • [5] Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    Shah, MH
    Young, D
    Kindler, HL
    Webb, I
    Kleiber, B
    Wright, J
    Grever, M
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6111 - 6118
  • [6] A phase II trial of PS-341 in metastatic breast cancer (MBC)
    Cristofanilli, M
    Gonzalez-Angulo, AM
    Nealy, KN
    Booser, D
    Pusztai, L
    Walters, RD
    Hortobagyi, GN
    Reuben, J
    Esseltine, D
    Wright, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 220S - 220S
  • [7] A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gonzalo Gomez-Abuin
    Eric Winquist
    Walter M. Stadler
    Greg Pond
    Pamela Degendorfer
    John Wright
    Malcolm J. Moore
    [J]. Investigational New Drugs, 2007, 25 : 181 - 185
  • [8] A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gomez-Abuin, Gonzalo
    Winquist, Eric
    Stadler, Walter M.
    Pond, Greg
    Degendorfer, Pamela
    Wright, John
    Moore, Malcolm J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2007, 25 (02) : 181 - 185
  • [9] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [10] Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects
    Shahshahan, Mohammad A.
    Beckley, Maureen N.
    Jazirehi, Ali R.
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (07): : 913 - 924
12345